Approximately 625,000 Shares Of Cabaletta Bio Inc. (CABA) Were Sold By This Insider.

Cabaletta Bio Inc. (NASDAQ:CABA) trading with an addition of $0.4 to $11.19 on Friday, an upside of 3.71 percent. An average of 210,511 shares of common stock have been traded in the last five days. There was a fall of -$0.59 in the past week. The last 20 days have seen an average of 155,373 shares traded, while the 50-day average volume stands at 176,775.

CABA stock has increased by 1.36% in the last month. The company shares reached their 1-month lowest point of $10.25 on 10/06/21. With the stock rallying to its 52-week high on 01/08/21, shares of the company touched a low of $7.00 and a high of $16.38 in 52 weeks. In spite of this, the price is down -31.68% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

31 days have passed since Cabaletta Bio Inc. (CABA) last reported insider trading activity. 5AM Ventures V, L.P., who is 10% Owner, most recently acquired $625,000 shares at $9.70 per share on Sep 07. In this transaction, the insider spent $6,062,500. 10% Owner, 5AM Ventures V, L.P., disposed of 85,000 shares at a price of $13.00 on Jan 12. The insider now owns more than $1,105,000 worth of shares. Prior to that, 10% Owner 5AM Ventures V, L.P. went on to Sale 302,000 shares at $13.00 each on Jan 08. An amount of $3,926,000 was transacted.

Valuation Metrics

Cabaletta Bio Inc. (CABA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.97 for the sector. This means investors are optimistic about the stock’s future prospects. Other valuation ratios to consider include the price-to-book (PB) ratio at 2.63.

The quick ratio of Cabaletta Bio Inc. for the three months ended June 29 was 18.70, and the current ratio was 18.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Cabaletta Bio Inc.’s return on assets was -34.20%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Cabaletta Bio Inc. had $3.31 million in cash. The analyst consensus anticipated Cabaletta Bio Inc.’s latest quarter earnings to come in at -$0.5 per share, but it turned out to be -$0.45, a 10.00% surprise. At the end of the quarter ending June 29, Cabaletta Bio Inc.’s stock balance sheet showed total liabilities of 5.6 million. Shareholders own equity worth $24.97 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Cabaletta Bio Inc. (CABA) price momentum. RSI 9-day as of the close on 07 October was 45.84%, suggesting the stock is Neutral, with historical volatility in this time frame at 40.27%.

As of today, CABA’s price is $11.21 -4.97% or -$0.59 from its 5-day moving average. CABA is currently trading -2.67% lower than its 20-day SMA and +10.36% higher than its 100-day SMA. However, the stock’s current price level is +44.56% above the SMA50 and -12.00% below the SMA200.

The stochastic %K and %D were 28.95% and 21.87%, respectively, and the average true range (ATR) was 0.72. With the 14-day stochastic at 41.43% and the average true range at 0.72, the RSI (14) stands at 50.94%. The stock has reached -0.61 on the 9-day MACD Oscillator while the 14-day reading was at -0.87.

Analyst Ratings

Mizuho launched coverage on Cabaletta Bio Inc. (NASDAQ: CABA) in its analyst report released on June 30, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Cabaletta Bio Inc. (CABA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CABA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.

What is CABA’s price target for the next 12 months?

Analysts predict a range of price targets between $20.00 and $28.00, with a median target of $22.00. Taking a look at these predictions, the average price target given by analysts for Cabaletta Bio Inc. (CABA) stock is $22.60.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam